This prospective, nonrandomized, interventional design study was conducted according to the tenets of the Declaration of Helsinki, and received authorization from the South Mediterranean IV ethical board committee for human research and from the French regulation agency for medication. All study participants provided oral and written informed consent. Patients were recruited, examined, and tested at the Gui de Chauliac Hospital, Institut des Neurosciences de Montpellier in Montpellier, France. Patients with a clinical diagnosis of adRP carrying the p.Gly56Arg mutation in NR2E3 gene were selected from a genetic sensory disease database and the mutation was confirmed by direct sequencing.
Charts of affected members in two families were reviewed to exclude those with any other cause of visual loss other than the primary ocular diagnosis of retinal degeneration. Nine patients were available to undergo a standard ophthalmologic examination, which included visual acuity, static perimetry (MonPack1, [STAT-10] 56 points, central 10 deg; Metrovision, Pérenchies, France), automated kinetic perimetry (MonPack1; Metrovision), optical coherence tomography (OCT Stratus, program macular thickness map; Carl Zeiss, Dublin, CA), and an experimental intervention, which was pupil testing with a computerized chromatic pupillometer (see Methods below). The following information was recorded from the hospital chart: date and results of most recent full-field ERG, fundus description, and/or photographic documentation.
Nine healthy volunteers were recruited from hospital personnel and 2 from accompanying persons of patients. One boy who was the son of one of the investigators (AK) also served as control subject and consent was obtained from the non-investigator parent. These 12 control subjects had a normal ophthalmologic examination and no history of ocular disease other than refractive error, and were not using topical or systemic medications known to affect the pupil light reflex.